CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Leonard Schleifer

Co-Founder, President, CEO & Co-Chairman, Regeneron

Search every verified Leonard Schleifer interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Leonard Schleifer, co-founder, president, and CEO of Regeneron Pharmaceuticals, discussed the company's financial performance and strategic priorities during recent earnings calls. In the fourth quarter 2024 call, he highlighted the initiation of a quarterly cash dividend and an additional $3 billion share repurchase authorization, increasing total buyback capacity to approximately $4.5 billion, while stating that this would not alter the company's focus on heavy investment in its business. He also referenced ten differentiated mid- and late-stage pipeline opportunities presented at the JP Morgan conference, which he said could collectively address a market opportunity of over $220 billion. On the second quarter 2026 call, Schleifer addressed capital allocation and potential transactions, stating that he was not averse to M&A but was averse to overpaying, and noted productive early discussions with the new CEO of another company regarding potential collaborations on assets. He also commented on the company's approach to research and development, emphasizing a diversified strategy across multiple therapeutic areas rather than concentrating on a single indication or disease.

Recent appearances

Notable quotes

“I have watched our industry evolve since I got into this business 1988. You got a lot of value back in 1988 if you had a group of smart people and a prestigious scientific advisory board and an idea. And then this sliding lever moved along in different places. Sometimes you had to have pre-clinical data. Then you had to have phase one data safe. Then you had to have proof of concept and it kept sliding around and the”

“I don't think we get any credit for our pipeline because if you look at what the revenue projections for Dupixent, you get all your value back from Dupixent, not to mention the $18 billion we have in the bank. So, there is a disconnect that people aren't paying enough attention to the pipeline.”

“We're not going to make any money on this, but maybe we learn about how that gene interacts — it could inform treatments for age‑related hearing loss and other disorders.”

“When there are small companies doing it, there has to be a path for investors to get something — if there isn't a path, the capital is not going to be there. Our system works based on these kinds of incentives, though large companies like Regeneron can sometimes pursue ultra‑rare disease programs or even give therapies away.”

Other executives at Regeneron

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →